Pimavanserin for Psychosis in Parkinson ’s Disease Dementia: Subgroup Analysis of the HARMONY Trial
Background: Pimavanserin is FDA-approved to treat Parkinson ’s disease (PD) psychosis. We analyzed the effect of pimavanserin on psychosis in the PD dementia (PDD) subgroup from the phase 3 HARMONY trial. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: D. Weintraub, A.J. Espay, V.D. Sharma, P.N. Tariot, V. Abler, S. Pathak, S. Stankovic Source Type: research
Validation of GWAS-Identified Risk Loci for Parkinson ’s Disease in the Chinese Population
Background: The largest genome-wide association study (GWAS) for Parkinson ’s disease (PD) has identified over 90 risk loci in the European population. However, these risk loci still lacked further replication, especially in cohorts from different ethnic background. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: C. Li, R. Ou, Y. Hou, Q. Wei, L. Zhang, J. Lin, K. Liu, J. Huang, X. Chen, W. Song, B. Zhao, Y. Wu, H. Shang Source Type: research
Interaction between sex and GBA mutations influences clinical phenotype in Parkinson disease
Background: Biological sex differences are known to be an important factor with clinical implications in Parkinson's disease (PD). However, the role of sex in the context of PD genetic background remains largely unexplored. GBA mutations are a well-known genetic risk factor for PD. We investigated the potential interaction of sex and GBA mutations on the heterogenicity of PD clinical phenotype. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: L. Gallo, M. Avenali, S. Caminiti, P. Mitrotti, M. Pocora, G. Cuconato, I. Palmieri, C. Pasquini, C. Galandra, R. Calabrese, R. Zangaglia, C. Tassorelli, A.V.H. Schapira, E.M. Valente, F. Blandini Source Type: research
Machine Learning Analysis of the Interaction Between miR-155 and LRRK2 Gene Variants in Parkinson's Disease Progression
This study aims to investigate this connection and its impact on the progression of PD. We utilize advanced machine learning techniques to thoroughly analyze genetic, epigenetic, and clinical data. The focus on this relationship is intended to provide new understanding and insight s into the molecular dynamics driving PD progression. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: R. Fajar, M. Caroline, S.Z. Martinah Source Type: research
Combined Assessment of GCase Activity and α-synuclein as a Promising Blood Biomarker for GBA Mutation Carriers
Background: Glucocerebrosidase (GBA) mutations are the most frequent genetic risk factors for Parkinson Disease (PD). Decreased glucocerebrosidase activity (GCase) and increased α-synuclein (α-syn) levels are both considered promising biomarkers for GBA-PD. However, the role of combined blood GCase/α-synuclein is still poorly investigated. The present study investigates whether combined evaluation of blood GCase and α-synuclein can predict disease severity in GBA-PD and prodromal features in asymptomatic GBA-carriers (GBA-nonPD). (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: C. Pasquini, M. Avenali, S.P. Caminiti, S. Cerri, M. Gegg, M. Toffoli, G. Ongari, D. Hughes, C. Cerami, C. Crespi, E.M. Valente, A.H.V. Schapira, F. Blandini Source Type: research
